Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis UCSF
Dates
study started
completion around

Description

Summary

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

Official Title

A Phase 2 Study of Olaparib in Combination With Pembrolizumab in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer

Keywords

Solid Tumors, Pembrolizumab, Olaparib, Olaparib+Pembrolizumab

Eligibility

Locations

  • UC Davis Comprehensive Cancer Center ( Site 0039)
    Sacramento California 95817 United States
  • University of California San Francisco ( Site 0015)
    San Francisco California 94158 United States
  • San Francisco Oncology Associates ( Site 0085)
    San Francisco California 94115 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Merck Sharp & Dohme LLC
Links
Merck Clinical Trials Information Plain Language Summary
ID
NCT04123366
Phase
Phase 2 Solid Tumor Research Study
Study Type
Interventional
Participants
Expecting 300 study participants
Last Updated